evalu
put
antiarthrit
activ
sarscov
fp
use
sarscov
fpderiv
peptid
sequenc
mwktptlkyfg
peptid
includ
charg
distribut
pattern
two
essenti
posit
charg
amino
acid
residu
underlin
space
apart
four
amino
acid
similar
chain
tmd
either
human
vigfrilllkvagfnllmtl
mous
svmglrilllkvagfnllmtl
origin
base
school
model
sequenc
previous
hypothes
similar
immunomodulatori
activ
tcr
cp
glrilllkv
hiv
sar
cov
fp
peptid
mutant
two
function
import
lysin
replac
glycin
use
neg
control
peptid
use
cia
mous
model
commonli
studi
autoimmun
model
rheumatoid
arthriti
ra
sinc
vast
major
studi
immunomodulatori
activ
tcr
cp
hiv
fp
done
anim
model
autoimmun
intraperiton
ip
administ
daili
dose
mgkg
significantli
suppress
arthriti
sever
compar
administr
vehicl
control
peptid
mgkgday
shown
fig
differ
vehicl
group
start
day
continu
day
day
mean
sem
clinic
arthriti
score
mice
cia
much
lower
mice
versu
p
effect
dosedepend
antiarthrit
activ
observ
free
ip
administ
daili
dose
mgkg
data
shown
previous
report
incorpor
anoth
immunomodulatori
peptid
employ
school
mechan
action
target
trigger
receptor
express
myeloid
cell
synthet
hdllike
nanoparticl
spheric
shape
shdl
significantli
reduc
effect
therapeut
dosag
anim
model
sepsi
lung
cancer
evalu
whether
incorpor
shdl
may
similar
effect
shdlbound
ip
administ
daili
dose
mgkg
despit
decreas
administr
dose
arthriti
inhibitori
effect
observ
mgkgday
compar
observ
mgkgday
peptid
free
form
fig
although
underli
molecular
mechan
phenomenon
complet
understood
need
investig
one
suggest
result
prolong
circulatori
halflif
shdlbound
vivo
peptid
halflif
short
typic
shdl
character
much
longer
halfliv
interestingli
contrast
vehicl
mice
administr
daili
dose
mgkg
shdlbound
daili
dose
mgkg
result
increas
bodi
weight
compar
observ
nonarthrit
mice
fig
c
summari
data
collect
indic
sarscov
fpderiv
peptid
gener
strong
antiarthrit
effect
cia
mous
model
ra
therebi
provid
first
experiment
vivo
evid
previous
predict
immunomodulatori
activ
sarscov
incorpor
spheric
hdllike
synthet
particl
substanti
reduc
effect
dosag
peptid
probabl
prolong
circulatori
halflif
afford
strategi
evalu
effect
suppress
cia
determin
whether
inhibit
chronic
inflamm
synovi
tissu
pannu
format
cartilag
destruct
bone
eros
next
examin
histopatholog
anim
joint
fig
overal
mice
treat
mgkgday
free
mgkgday
shdlbound
significantli
lower
joint
histopatholog
score
vehicl
group
p
fig
vehicletr
arthrit
mice
fore
hind
paw
joint
moder
inflamm
cartilag
damag
moder
pannu
bone
resorpt
well
mild
periost
bone
format
joint
fig
knee
joint
mark
inflamm
moder
cartilag
damag
pannu
format
bone
resorpt
periost
bone
format
shown
fig
ankl
joint
moder
inflamm
cartilag
damag
minim
pannu
bone
resorpt
well
mild
periost
bone
format
fig
markedli
thicken
synovi
membran
capsul
observ
result
pannu
format
inflammatori
cell
infiltr
shown
fig
chronic
inflamm
destroy
joint
line
includ
cartilag
nearbi
support
structur
bone
format
pannu
probabl
result
overgrowth
synoviocyt
observ
accumul
inflammatori
cell
led
deform
cartilag
bone
agre
observ
clinic
score
similar
histopatholog
joint
observ
anim
treat
mgkgday
shown
mice
treat
mgkgday
fore
hind
paw
joint
minim
inflamm
minim
cartilag
damag
fig
knee
ankl
joint
minim
inflamm
mild
evid
synovi
membran
thicken
pannu
format
fall
within
normal
limit
fig
similar
histopatholog
observ
mice
treat
shdlbound
mgkgday
fig
summari
histopatholog
examin
show
greatli
reduc
joint
inflamm
damag
mice
compar
vehicletr
mice
mice
treat
suggest
specif
protect
effect
peptid
signific
differ
observ
histopatholog
analysi
joint
limb
mice
treat
free
mgkgday
shdlbound
mgkgday
mention
prolong
halflif
peptid
incorpor
hdl
particl
probabl
one
reason
shdlbound
dose
mgkgday
similarli
effect
free
dose
mgkgday
investig
potenti
mechan
underli
effect
examin
serum
level
differ
cytokin
day
use
quantit
multiplex
elisa
array
mice
treat
free
mgkgday
shdlbound
mgkgday
cytokin
level
significantli
lower
vehicletr
mice
treat
g
mgkgday
fig
interestingli
treatment
reduc
serum
level
macrophag
colonystimul
factor
mcsf
play
import
proinflammatori
role
known
produc
varieti
includ
activ
elucid
molecular
mechan
underli
observ
immunomodulatori
effect
vivo
use
confoc
fluoresc
microscopi
demonstr
insert
cell
membran
coloc
tcr
cell
vitro
supplement
fig
summari
data
suggest
molecular
mechan
cia
suppress
includ
inhibit
cytokin
growth
factor
product
mediat
inflammatori
cell
thought
central
patholog
autoimmun
success
infect
replic
persist
host
virus
evolv
numer
strategi
take
control
multipl
cellular
process
includ
target
transmembran
signal
transduct
mediat
immun
receptor
includ
mirr
review
lymphotrop
virus
approach
allow
viru
inhibit
tcr
signal
disarm
receptor
success
enter
cell
virus
allow
evas
cell
respons
toward
infect
recent
report
tcrtarget
immunomodulatori
activ
mediat
hiv
suggest
fusion
peptid
function
fuse
virion
host
also
silenc
tcr
signal
pathway
interestingli
characterist
pattern
tcrtarget
inhibitori
activ
hiv
fp
strikingli
similar
tcr
cp
peptid
coloc
tcr
cell
membran
inhibit
antigen
cell
activ
vitro
suppress
autoimmun
arthriti
peptid
suggest
treatment
cellmedi
patholog
includ
inflammatori
skin
diseas
addit
tcr
cp
shown
human
studi
proper
treatment
human
cellmedi
dermatos
substitut
molecular
mechan
action
clinic
relev
peptid
first
explain
school
later
base
school
model
primari
sequenc
analysi
varieti
viral
fp
includ
sarscov
fp
hypothes
similar
hiv
fp
fp
may
fusogen
also
tcrtarget
immunomodulatori
activ
school
model
togeth
lesson
learn
viral
pathogenesi
use
practic
ration
drug
design
develop
new
therapi
immun
mention
amino
acidlong
hydrophob
stretch
correspond
residu
myktptlkyfggfnfsqil
recent
identifi
put
fusion
peptid
sarscov
present
studi
order
provid
compel
experiment
vivo
evid
support
use
school
model
design
synthet
peptid
myktptlkyfg
deriv
sarscov
fp
sequenc
posit
two
essenti
posit
charg
lysin
residu
underlin
space
four
amino
acid
model
suggest
charg
distribut
pattern
function
import
provid
tcrtarget
inhibitori
hypothesi
correct
peptid
demonstr
immunomodulatori
activ
vivo
similar
demonstr
earlier
tcr
cp
hiv
fp
anim
model
autoimmun
sar
cov
fp
peptid
mutant
lysin
replac
glycin
use
neg
control
peptid
accord
school
peptid
compet
recognit
subunit
bind
signal
homo
heterodim
fig
thu
inhibit
tcr
signal
discrep
found
prior
studi
immunomodulatori
activ
tcr
inhibitori
tm
peptid
vitro
activ
observ
vivo
antiarthrit
activ
observ
rat
adjuvantinduc
arthriti
aia
studi
move
directli
vivo
studi
test
peptid
cia
model
autoimmun
arthriti
circulatori
halflif
peptid
vivo
short
typic
order
prolong
halflif
test
present
studi
whether
peptid
incorpor
shdl
nanoparticl
mimic
human
hdl
group
nativ
lipoprotein
transport
cholesterol
peripher
tissu
liver
readili
reconstitut
vitro
lipid
apolipoprotein
apo
due
halflif
nativ
shdl
normal
subject
particl
repres
promis
versatil
deliveri
platform
peptid
therapeut
synthet
reconstitut
hdl
sever
competit
advantag
compar
deliveri
platform
apo
ai
major
hdl
protein
endogen
protein
trigger
immunoreact
small
size
nm
allow
hdl
enter
accumul
tissu
organ
area
interest
varieti
drug
imag
agent
incorpor
respect
therapeut
human
apo
ai
larg
protein
purifi
human
plasma
thu
addit
immens
monetari
cost
purif
develop
apo
aicontain
therapeut
agent
would
requir
number
safeti
precaut
follow
complic
transit
clinic
practic
previous
demonstr
synthet
apo
ai
peptid
function
replac
nativ
apo
ai
protein
hdl
encourag
develop
hdlbase
deliveri
platform
present
studi
synthet
shdl
contain
apo
ai
peptid
success
load
subsequ
purifi
character
use
varieti
biophys
procedur
first
studi
test
previous
predict
immunomodulatori
activ
sarscov
expect
antiarthrit
activ
demonstr
anim
model
autoimmun
arthriti
tcr
hiv
sarscov
fpderiv
peptid
sequenc
significantli
suppress
cia
mice
peptid
mgkgday
inhibit
inflamm
cia
assess
clinic
evalu
score
diseas
fig
histolog
analysi
joint
reveal
substanti
reduc
joint
inflamm
protect
cartilag
damag
abrog
bone
eros
reduc
system
bone
loss
fig
effect
specif
control
peptid
administ
daili
dose
mgkg
affect
cia
incorpor
shdl
reduc
effect
dosag
peptid
free
form
mgkgday
shdlbound
mgkgday
show
similar
antiarthrit
effect
cia
clinic
histolog
interestingli
mice
treat
free
daili
dose
mgkg
exhibit
signific
diseas
improv
compar
vehicletr
mice
shown
molecular
level
activ
cell
mediat
product
multipl
cytokin
growth
factor
known
involv
pathogenesi
mani
molecul
serv
target
cytokineblock
therapi
current
develop
eg
differ
phase
clinic
trial
eg
mcsf
approv
eg
blocker
present
studi
significantli
reduc
serum
cytokin
level
observ
mice
treat
compar
vehicletr
arthrit
mice
mice
treat
fig
coloc
tcr
cell
membran
supplement
fig
support
suggest
molecular
mechan
observ
immunomodulatori
activ
peptid
find
consist
previous
report
tcr
cp
hiv
summari
data
present
studi
provid
first
experiment
evid
previous
predict
immunomodulatori
activ
sar
cov
demonstr
strong
antiarthrit
effect
sar
cov
fpderiv
amino
acidlong
peptid
sequenc
mous
model
ra
interestingli
immunosuppress
activ
influenza
fp
recent
demonstr
suggest
short
synthet
peptid
school
peptid
design
line
school
platformbas
strategi
therapeut
inhibit
modul
varieti
function
unrel
multichain
receptor
express
variou
cell
molecular
mechan
action
school
peptid
similar
virus
use
evad
immun
date
school
peptid
target
glycoprotein
receptor
vi
gpvi
tcr
demonstr
vitro
vivo
repres
promis
therapeut
approach
treatment
varieti
diseas
unmet
clinic
need
includ
sepsi
lung
cancer
rheumatoid
arthriti
dermatos
taken
togeth
find
support
unifi
viral
immun
evas
strategi
develop
optim
million
year
evolut
virushost
interact
practic
use
ration
drug
design
new
mechanismbas
therapi
popc
purchas
avanti
polar
lipid
alabast
al
sodium
cholat
cholesterol
cholesteryl
oleat
chemic
purchas
sigma
aldrich
compani
st
loui
mo
follow
synthet
peptid
order
american
peptid
compani
sunnyval
ca
sarscov
fusion
peptidederiv
sequenc
mwktptlkyfg
sarscov
spike
glycoprotein
control
peptid
mwgtptlgyfg
two
peptid
pylddfqkkwqeemelyrqkv
plgeemrdrarahvdalrthla
correspond
human
apo
ai
helix
respect
peptid
purifi
reversedphas
highperform
liquid
chromatographi
rphplc
puriti
confirm
amino
acid
analysi
mass
spectrometri
spheric
hdl
complex
synthes
sodium
cholat
dialysi
procedur
essenti
molar
ratio
popc
cholesterol
cholesteryl
oleat
apo
ai
sodium
cholat
briefli
popc
cholesterol
cholesteryl
oleat
organ
solvent
mix
dri
stream
argon
place
vacuum
h
lipid
film
dispers
trisbuff
salineedta
tbsedta
ph
sonic
min
dispers
lipid
aqueou
solut
propylen
glycol
ethanol
ad
amount
peptid
control
vari
differ
prepar
sodium
cholat
solut
ad
mixtur
incub
min
cool
solut
contain
mixtur
apo
ai
peptid
pb
ph
ad
mixtur
incub
h
follow
extens
dialysi
pb
remov
sodium
cholat
obtain
particl
purifi
calibr
superdex
gel
filtrat
column
ge
healthcar
bioscienc
pittsburgh
pa
use
biocad
workstat
appli
biosystem
carlsbad
ca
character
analyt
rphplc
nondenatur
gel
electrophoresi
describ
final
peptid
composit
determin
prepar
particl
analyt
rphplc
previous
mean
size
particl
determin
use
electron
microscopi
anim
studi
perform
bolder
biopath
boulder
co
anim
experi
perform
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
nih
unit
state
depart
agricultur
usda
anim
welfar
act
cfr
part
protocol
approv
institut
anim
care
use
committe
iacuc
bolder
biopath
complianc
regul
prior
studi
initi
anim
welfar
assur
number
method
perform
accord
approv
protocol
male
week
old
mice
harlan
indianapoli
anaesthet
isofluran
veton
bois
id
inject
intraderm
freund
complet
adjuv
sigma
aldrich
compani
st
loui
mo
mgml
final
concentr
contain
bovin
type
ii
collagen
bolder
biopath
boulder
co
mgml
final
concentr
base
tail
day
day
day
mice
random
bodi
weight
treatment
group
mice
weigh
approxim
gram
mean
g
enrol
day
treatment
initi
mice
ip
inject
mgkgday
mgkgday
pb
day
begin
day
arthriti
onset
occur
day
mice
weigh
studi
day
prior
necropsi
daili
clinic
score
given
scale
paw
right
front
left
front
right
rear
left
rear
day
use
follow
criteria
normal
one
hind
fore
paw
joint
affect
minim
diffus
erythema
swell
two
hind
fore
paw
joint
affect
mild
diffus
erythema
swell
three
hind
fore
paw
joint
affect
moder
diffus
erythema
swell
four
hind
fore
paw
joint
affect
mark
diffus
erythema
swell
entir
paw
affect
sever
diffus
erythema
sever
swell
unabl
flex
digit
day
mice
human
euthan
necropsi
mice
anesthet
isofluran
bled
cardiac
punctur
serum
prepar
store
frozen
cytokin
analysi
histolog
fore
paw
hind
paw
knee
harvest
place
neutral
buffer
formalin
nbf
day
fix
day
formic
acid
decalcif
tissu
trim
process
paraffin
embed
section
stain
toluidin
blue
blue
hind
paw
fore
paw
knee
embed
section
frontal
plane
six
joint
anim
process
histopatholog
evalu
joint
assess
inflamm
scale
pannu
format
scale
cartilag
damag
scale
bone
resorpt
scale
periost
new
bone
format
scale
sum
histopatholog
score
also
determin
sum
five
paramet
serum
sampl
collect
day
cytokin
analyz
use
quantibodi
mous
cytokin
array
kit
raybiotech
norcross
ga
follow
manufactur
instruct
data
analys
perform
use
prism
graphpad
softwar
inc
la
jolla
ca
result
express
mean
sem
statist
differ
analyz
use
analysi
varianc
bonferroni
adjust
p
valu
less
consid
signific
antiarthrit
activ
demonstr
fusion
peptid
sever
acut
respiratori
syndrom
coronaviru
sarscov
vivoth
peptid
substanti
decreas
cytokin
releas
vivoincorpor
peptid
nanoparticl
significantli
increas
peptid
dosag
efficaci
access
code
access
number
uniprotkbswissprot
knowledgebas
http
wwwexpasyorgsprot
protein
sequenc
discuss
research
articl
follow
cell
receptor
alpha
chain
human
mous
sarscov
cite
articl
shen
z
sigalov
b
sar
coronaviru
fusion
peptidederiv
sequenc
suppress
collageninduc
arthriti
mice
sci
rep
doi
